Bayer Gets Positive Phase 2 Results for Eliapixant in Refractory Chronic Cough

Dienstag, 03.08.2021 14:35 von PLX

• (PLX AI) – Bayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profile, the company says.
• • Positive Phase IIb results for eliapixant in patients with refractory chronic cough
• • The Phase IIb clinical trial evaluated the efficacy and safety of its investigational orally administered, potent and selective P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough
• • The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment
• • The data showed a favorable safety and tolerability profile
• • In addition to refractory chronic cough, eliapixant is currently being evaluated in Phase II clinical trials for the treatment of endometriosis, overactive bladder and neuropathic pain